RxDoctor Payments Data

Jeffrey Garman, DO

Internal Medicine · Sandusky, OHNPI 1750319562

Payments from drug & device makers

$12,948in general payments, 2019–2025

Across 854 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Amgen$1K
  • GSK$798
  • Merck$765
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$12,936100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)147$2,462
Novo Nordisk115$1,454
AstraZeneca78$1,421
Amgen(2 entities)55$1,022
GSK68$798
Merck56$765
Pfizer58$737
Bayer25$449
Boehringer Ingelheim24$369
Novartis25$359
Lilly USA, LLC18$279
Amarin Pharma, Inc.17$265
Johnson & Johnson22$248
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$223
Kowa Pharmaceuticals America, Inc.19$218
Astellas Pharma US Inc11$177
Dexcom, Inc.6$121
Exact Sciences6$114
E.r. Squibb & Sons, L.L.C.8$113
Abbott5$103
Otsuka America Pharmaceutical, Inc.6$99
Teva Pharmaceuticals USA, Inc.7$91
Nestle Healthcare Nutrition Inc.5$77
Daiichi Sankyo Inc.4$77
Phathom Pharmaceuticals, Inc.3$60
Biohaven Pharmaceuticals, Inc.3$59
Sanofi-aventis U.S. LLC4$56
Biohaven Pharmaceutical Holding Company Ltd.3$48
Sanofi Pasteur Inc.2$46
Eisai Inc.2$39
Corcept Therapeutics2$39
Esperion Therapeutics, Inc.2$37
Axsome Therapeutics, Inc.2$35
Aimmune Therapeutics, Inc.2$33
Ultragenyx Pharmaceutical Inc.2$31
Biogen2$30
Ferring Pharmaceuticals Inc.2$30
Lundbeck LLC2$29
Mylan Specialty L.p.2$28
Otsuka Pharmaceutical Development & Commercialization, Inc.1$27
Biomarin Pharmaceutical Inc.1$25
Vital Connect, Inc1$24
Pacira Pharmaceuticals Incorporated1$19
Avadel CNS Pharmaceuticals, LLC1$17
OPKO Pharmaceuticals, LLC1$17
Vanda Pharmaceuticals Inc.1$17
Takeda Pharmaceuticals U.S.A., Inc.1$16
Avanir Pharmaceuticals, Inc.1$16
Vyera Pharmaceuticals, LLC1$16
Radius Health, Inc.1$16
Medtronic1$16
Amneal Pharmaceuticals LLC1$14
Currax Pharmaceuticals LLC1$14
IBSA Pharma Inc.1$14
Inogen, Inc.1$14
Shield Therapeutics Inc1$14
Clarus Therapeutics Inc.1$13

How this compares

$12,948 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$228,640
Medicare patients
470
Services billed
3,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$228,823
JardianceEmpagliflozin109$147,643
EliquisApixaban148$133,429
TrulicityDulaglutide60$94,242
RybelsusSemaglutide41$87,258
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$63,397
XareltoRivaroxaban52$58,924
MounjaroTirzepatide45$57,438
JanuviaSitagliptin Phosphate35$38,720
CreonLipase/Protease/Amylase21$35,643
FarxigaDapagliflozin Propanediol29$30,125
TradjentaLinagliptin18$23,411
UbrelvyUbrogepant13$20,906
JanumetSitagliptin Phos/Metformin Hcl17$16,825
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$16,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,454$316,082189 claims
Boehringer IngelheimJardiance, Tradjenta$369$171,054127 claims
Lilly USA, LLCTrulicity, Mounjaro$279$151,680105 claims
PfizerEliquis$737$133,429148 claims
GSKTrelegy Ellipta, Anoro Ellipta$798$79,62996 claims
Johnson & JohnsonXarelto$248$58,92452 claims
AbbVieCreon, Ubrelvy$2,462$56,54934 claims
MerckJanuvia, Janumet$765$55,54552 claims
AstraZenecaFarxiga$1,421$30,12529 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$6,150638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →